Hyloris Pharmaceuticals SA (EBR:HYL)
Belgium · Delayed Price · Currency is EUR 3.720
-0.230 (-5.82%)
Oct 9, 2026, 5:07 PM CET
Hyloris Pharmaceuticals Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 8.89 | 7.21 | 8.46 | 2.09 | 0.9 | 3.1 |
Other Revenue | 0.94 | 0.73 | 1.3 | 1.67 | 1.49 | - |
| 9.83 | 7.94 | 9.76 | 3.76 | 2.39 | 3.1 | |
Revenue Growth | 16.17% | -18.66% | 159.64% | 57.48% | -22.90% | 1669.14% |
Cost of Revenue | 0.55 | 0.38 | 0.23 | 0.09 | 0.09 | 0.11 |
Gross Profit | 9.28 | 7.56 | 9.53 | 3.67 | 2.29 | 2.99 |
Selling, General & Admin | 5.21 | 4.88 | 5.63 | 5.55 | 3.52 | 2.9 |
Research & Development | 10.47 | 11.28 | 10.27 | 14.42 | 10.27 | 5.03 |
Other Operating Expenses | -0.36 | -0.46 | 0.01 | -0.46 | 0.01 | 5.38 |
Operating Expenses | 15.32 | 15.71 | 15.9 | 19.51 | 13.8 | 13.31 |
Operating Income | -6.04 | -8.15 | -6.37 | -15.85 | -11.51 | -10.33 |
Interest Expense | -0.06 | -0.07 | -0.08 | -0.05 | -0.22 | -0.56 |
Interest & Investment Income | 0.21 | 0.4 | 0.9 | 0.87 | 0.07 | 0.03 |
Earnings From Equity Investments | -0.18 | -0.07 | -0.08 | -0.15 | -0.13 | -0.19 |
Currency Exchange Gain (Loss) | 0.11 | -0.41 | 0.26 | 0.02 | 0.35 | -0.19 |
Other Non Operating Income (Expenses) | 0.16 | 0.18 | -0.3 | -0.22 | -0.23 | -0.03 |
EBT Excluding Unusual Items | -5.8 | -8.12 | -5.66 | -15.38 | -11.68 | -11.26 |
Gain (Loss) on Sale of Investments | 0.97 | 0.97 | -0.97 | - | - | - |
Asset Writedown | - | - | - | - | - | -0.02 |
Legal Settlements | - | - | 0.29 | - | - | - |
Other Unusual Items | 0.44 | 0.44 | - | - | -0.23 | - |
Pretax Income | -4.87 | -6.71 | -6.34 | -15.38 | -11.9 | -11.28 |
Income Tax Expense | -0.21 | -0.37 | - | - | 0 | 0.3 |
Earnings From Continuing Operations | -4.65 | -6.33 | -6.34 | -15.38 | -11.91 | -11.58 |
Net Income | -4.65 | -6.33 | -6.34 | -15.38 | -11.91 | -11.58 |
Net Income to Common | -4.65 | -6.33 | -6.34 | -15.38 | -11.91 | -11.58 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 28 | 28 | 28 | 28 | 27 | 26 |
Shares Outstanding (Diluted) | 28 | 28 | 28 | 28 | 27 | 26 |
Shares Change | 2.09% | - | - | 2.95% | 5.29% | 18.40% |
EPS (Basic) | -0.17 | -0.23 | -0.23 | -0.55 | -0.44 | -0.45 |
EPS (Diluted) | -0.17 | -0.23 | -0.23 | -0.55 | -0.44 | -0.45 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -7.83 | -6.99 | -7.22 | -13.11 | -13.12 | -11.36 |
Free Cash Flow Per Share | -0.28 | -0.25 | -0.26 | -0.47 | -0.48 | -0.44 |
Gross Margin | 94.41% | 95.23% | 97.67% | 97.53% | 96.06% | 96.54% |
Operating Margin | -61.43% | -102.61% | -65.26% | -421.55% | -482.11% | -333.50% |
Profit Margin | -47.36% | -79.78% | -64.98% | -409.15% | -498.78% | -374.00% |
Free Cash Flow Margin | -79.69% | -88.08% | -74.00% | -348.66% | -549.69% | -366.83% |
EBITDA | -5.85 | -8.03 | -6.22 | -15.67 | -11.43 | -10.27 |
EBITDA Margin | -59.48% | -101.12% | -63.70% | - | - | - |
D&A For EBITDA | 0.19 | 0.12 | 0.15 | 0.18 | 0.08 | 0.05 |
EBIT | -6.04 | -8.15 | -6.37 | -15.85 | -11.51 | -10.33 |
EBIT Margin | -61.43% | -102.61% | -65.26% | - | - | - |